Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 275 Carcinoma, Intraductal, Noninfiltrating 25 Breast Carcinoma In Situ 21 Neoplasm Metastasis 14 Neoplasms 13 Breast Neoplasms, Male 12 Ovarian Neoplasms 10 Inflammatory Breast Neoplasms 7 Glioblastoma 6 Endometrial Neoplasms 6 Prostatic Neoplasms 5 Central Nervous System Neoplasms 5 Gliosarcoma 4 Fallopian Tube Neoplasms 4 Breast Cancer Female 4 Brain Neoplasms 4 Recurrence 3 Obesity 3 Hot Flashes 3 Glioma 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Ductal, Breast 3 Breast Diseases 3 Astrocytoma 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Sleep Wake Disorders 2 Sarcoma 2 Pancreatic Neoplasms 2 Oligodendroglioma 2

Interventions

Exercise 2 College Fraternities and Sororities 2 bazedoxifene 1 Tamoxifen 1 Surveys and Questionnaires 1 Risk Assessment 1 Radon 1 Price Transparency 1 Preoperative Exercise 1 Nutritional Support 1 Nutrition Assessment 1 Health Communication 1 Ethanol 1 Estrogens, Conjugated (USP) 1 Counseling 1 Adiposity 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Risk Reduction Behavior × Tamoxifen × Clear all

NCT03346200 2025-03-07

KARISMA2

Karolinska Institutet

Phase 2 Completed

1,440 enrolled 14 charts

Breast Neoplasms, Risk Reduction Behavior

Data powered by HemOnc (CC BY 4.0) Colophon ⚡